Vigil Neuroscience, Inc.
VIGLDelisted- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001827087
Vigil Neuroscience, Inc. was delisted in 2025; its insiders filed their last Form 4 on Aug 7, 2025; 78 institutions reported holding it in 13F filings for Q2 2025, worth $265.8M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 78
- Q2 2025, +28 vs. previous quarter
- 13F value
- $265.8M
- Reported value at the end of Q2 2025
- Superinvestors holding
- 0
- At the end of Q2 2025
Superinvestors holding VIGL, Q2 2025
No superinvestor reported holding VIGL at the end of Q2 2025.
Latest insider trades
Open-market purchases and sales by Vigil Neuroscience, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 19, 2024 (view filing) | Dec 19 | Same day | Budd Haeberlein Samantha L.Director | PPurchase | +12.0K | $1.71 | +$20.5K | New position12.0K after | |
| Dec 19, 2024 (view filing) | Dec 19 | Same day | Magovcevic-Liebisch IvanaPresident and CEO | PPurchase | +5.00K | $1.68 | +$8.40K | +2.3%222.7K after | |
| Dec 18, 2024 (view filing) | Dec 18 | Same day | Magovcevic-Liebisch IvanaPresident and CEO | PPurchase | +5.00K | $1.67 | +$8.35K | +2.4%217.7K after | |
| Dec 5, 2024 (view filing) | Dec 5 | Same day | Magovcevic-Liebisch IvanaPresident and CEO | PPurchase | +5.00K | $2.34 | +$11.7K | +2.4%212.7K after | |
| Nov 20, 2023 (view filing) | Nov 20 | Same day | Magovcevic-Liebisch IvanaPresident and CEO | PPurchase | +4.00K | $3.75 | +$15.0K | +2.0%207.7K after | |
| Nov 22, 2022 (view filing) | Nov 18 | 4 days | Papapetropoulos SpyridonChief Medical Officer | SSale | −300 | $14.00 | −$4.20K | −7.0%4.00K after | |
| May 17, 2022 (view filing) | May 16-17 | 1 day | Thorp ClayDirector | PPurchase | +36.7K | $2.85 | +$104.4K | +2.4%1.56M after | 2 lots |
| May 6, 2022 (view filing) | May 5 | 1 day | Thackaberry EvanSVP, Head of Early Development | PPurchase | +1.50K | $4.00 | +$6.00K | New position1.50K after | |
| May 4, 2022 (view filing) | May 3 | 1 day | Verni ChristopherGeneral Counsel | PPurchase | +4.00K | $3.77 | +$15.1K | New position4.00K after | |
| May 4, 2022 (view filing) | May 2-3 | 2 days | Magovcevic-Liebisch IvanaPresident and CEO | PPurchase | +5.00K | $3.68 | +$18.4K | +2.5%203.7K after | 2 lots |
Top 10 13F holders, Q2 2025
The largest institutional positions in Vigil Neuroscience, Inc. at the end of Q2 2025; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC | 5,836,874 | $46.4M | 7.01% | 00.0% | Unchanged |
| Beryl Capital Management LLC | 4,606,267 | $36.6M | 5.52% | +4,606,267 | New |
| Glazer Capital, LLC | 3,012,068 | $23.9M | 0.86% | +3,012,068 | New |
| Oddo BHF Asset Management SAS | 2,300,000 | $18.3M | 0.69% | +2,300,000 | New |
| 683 Capital Management, LLC | 1,261,772 | $10.0M | 1.02% | −478,228−27.5% | Reduced |
| Vanguard Group Inc | 1,260,942 | $10.0M | 0.00% | +212,119+20.2% | Added |
| Gabelli Funds LLC | 1,189,528 | $9.46M | 0.07% | +1,189,528 | New |
| Alpine Associates Management Inc. | 1,094,900 | $8.70M | 0.47% | +1,094,900 | New |
| Opaleye Management Inc. | 1,000,000 | $7.95M | 1.61% | +1,000,000 | New |
| Highbridge Capital Management LLC | 865,036 | $6.88M | 0.36% | +865,036 | New |